➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
McKinsey
Harvard Business School
Mallinckrodt
AstraZeneca

Last Updated: May 11, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR INFANT'S ADVIL

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for Infant's Advil

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT01732874 DHA-1 for Lactating Mothers Active, not recruiting Children's Hospital Medical Center, Cincinnati Phase 1/Phase 2 2012-11-01 The purpose of this research study is to find out whether preterm infants are receiving enough of the essential and long chain fatty acids important for brain development and immune function. Our current intravenous (IV) fats do not contain the long chain fatty acids and different milk sources have different compositions. We would like to evaluate lactating mothers dietary intake and breastmilk level of fatty acid status by doing an analysis of their blood and breastmilk samples after they have been supplemented with a currently used fatty acid supplement (DHA- Martek Biosciences, now known as Dutch State Mines (DSM) Nutritional Lipid) The DHA supplement is available over the counter. The information learned from this research study may benefit other mothers and babies in the future. The information could help make sure premature babies are receiving the right nutrients they need for appropriate growth and development.
New Dosage NCT03608696 Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure Not yet recruiting Chiesi Farmaceutici S.p.A. Phase 1/Phase 2 2018-08-29 Neonatal withdrawal syndrome is a series of signs and symptoms in infants exposed to opioids in utero. Buprenorphine has demonstrated a 40% reduction in length of pharmacologic treatment compared to oral morphine. These results were with an empirically derived dose. This study will use pharmacokinetic modeling-informed dosing to clarify the dose/response relationship and use a rational approach to define an optimal dose regimen. The clinical trial will be open label, single arm design with a goal of initial testing of a new dosing regimen.
New Dosage NCT03608696 Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure Not yet recruiting Thomas Jefferson University Phase 1/Phase 2 2018-08-29 Neonatal withdrawal syndrome is a series of signs and symptoms in infants exposed to opioids in utero. Buprenorphine has demonstrated a 40% reduction in length of pharmacologic treatment compared to oral morphine. These results were with an empirically derived dose. This study will use pharmacokinetic modeling-informed dosing to clarify the dose/response relationship and use a rational approach to define an optimal dose regimen. The clinical trial will be open label, single arm design with a goal of initial testing of a new dosing regimen.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Infant's Advil

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000494 Management of Patent Ductus in Premature Infants Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1978-09-01 To evaluate the effects (up to one year of age) of indomethacin on the clinical course of patent ductus arteriosus (PDA) in premature infants (24 hours old or less) and to assess the relative merits of indomethacin and surgery in infants with persistent respiratory distress who were not treated early with indomethacin. Two concurrent trials were performed.
NCT00000563 Prevention of Neonatal Respiratory Distress Syndrome With Antenatal Steroid Administration Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1976-06-01 To determine the effect of corticosteroids, administered 24 to 48 hours before parturition, on the incidence of neonatal respiratory distress syndrome (RDS) and to determine whether the therapy has any adverse short- or long-term (up to 36 months) effects on the infant. Secondarily, to determine whether the therapy has any adverse short-term effects on the mother and to determine whether morbidity rates for neonatal respiratory distress syndrome as well as total and cause-specific infant mortality rates differ between mothers who received antenatal steroids and those who received conventional medical care.
NCT00000578 NHLBI/NICHD Collaborative Studies of Asthma in Pregnancy Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 3 1994-04-01 To conduct a collaborative program of research on asthma and pregnancy consisting of two studies: the Asthma in Pregnancy Study (APS) was an observational study to evaluate relationships between asthma severity and treatment programs and perinatal outcome, and the Asthma Therapy in Pregnancy Trial (ATPT) was a randomized clinical trial of inhaled beclomethasone versus theophylline in the treatment of moderate asthma during pregnancy. Both studies were conducted in the Maternal-Fetal Medicine Unit (MFMU) Network, an ongoing group of participating obstetric centers supported by the National Institute of Child Health and Human Development. Studies were co-funded by the NHLBI.
NCT00000578 NHLBI/NICHD Collaborative Studies of Asthma in Pregnancy Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1994-04-01 To conduct a collaborative program of research on asthma and pregnancy consisting of two studies: the Asthma in Pregnancy Study (APS) was an observational study to evaluate relationships between asthma severity and treatment programs and perinatal outcome, and the Asthma Therapy in Pregnancy Trial (ATPT) was a randomized clinical trial of inhaled beclomethasone versus theophylline in the treatment of moderate asthma during pregnancy. Both studies were conducted in the Maternal-Fetal Medicine Unit (MFMU) Network, an ongoing group of participating obstetric centers supported by the National Institute of Child Health and Human Development. Studies were co-funded by the NHLBI.
NCT00000580 Interruption of Maternal-to-Infant Transmission of Hepatitis B by Means of Hepatitis B Immune Globulin Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1975-11-01 To evaluate whether hepatitis B immune globulin with a high level of antibody against the hepatitis B antigen would be capable of interrupting maternal-fetal transmission of hepatitis B virus, the single most important route of hepatitis spread in the entire Third World.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Infant's Advil

Condition Name

Condition Name for Infant's Advil
Intervention Trials
HIV Infections 65
Pregnancy 54
Malaria 21
Pain 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Infant's Advil
Intervention Trials
HIV Infections 71
Premature Birth 58
Malaria 35
Syndrome 28
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Infant's Advil

Trials by Country

Trials by Country for Infant's Advil
Location Trials
Thailand 100
Canada 62
South Africa 30
Argentina 30
United Kingdom 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Infant's Advil
Location Trials
California 81
Texas 68
North Carolina 60
New York 60
Pennsylvania 56
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Infant's Advil

Clinical Trial Phase

Clinical Trial Phase for Infant's Advil
Clinical Trial Phase Trials
Phase 4 133
Phase 3 157
Phase 2/Phase 3 28
[disabled in preview] 140
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Infant's Advil
Clinical Trial Phase Trials
Completed 307
Recruiting 133
Not yet recruiting 108
[disabled in preview] 94
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Infant's Advil

Sponsor Name

Sponsor Name for Infant's Advil
Sponsor Trials
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 65
National Institute of Allergy and Infectious Diseases (NIAID) 57
Bill and Melinda Gates Foundation 16
[disabled in preview] 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Infant's Advil
Sponsor Trials
Other 1138
NIH 197
Industry 126
[disabled in preview] 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Harvard Business School
Boehringer Ingelheim
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.